Agnes Koczo
banner
agneskoczo.bsky.social
Agnes Koczo
@agneskoczo.bsky.social
Cardiologist @UPMC/MWRI, former UPitt fellow/resident, passionate about care for cardiac problems in pregnancy/ACHD
Reposted by Agnes Koczo
New research presented at #ESCCongress shows women without traditional risk factors but with high inflammation face higher lifetime heart risks.

Recognizing these unique profiles is key to ensuring equitable patient outcomes.

Read more: academic.oup.com/eur...

#WomensHealth #CardioSky
September 13, 2025 at 12:30 PM
Reposted by Agnes Koczo
Our new review on the evidence for primary prevention aspirin in individuals with elevated Lp(a) is out now. #CardioSky

@ucsdcardiology.bsky.social @aspcardio.bsky.social @familyheartfdn.bsky.social

link.springer.com/epdf/10.1007...
April 9, 2025 at 3:47 PM
Reposted by Agnes Koczo
At #ACC25, we explored how to build successful trials through partnerships & innovation.

✅ Unique trial design can = diverse enrollment
✅ Start small, publish, & grow
✅ Industry interest follows proven patient enrollment

Thanks to Novo Nordisk & all who joined us!

#CardioSky
April 7, 2025 at 6:45 PM
Reposted by Agnes Koczo
Excited to hear updates on @janetweimd.bsky.social #NIH #R01 on myocardial steatosis in women with #CMD: defining the pathway to #HFpEF
#HFpEFSummit
March 20, 2025 at 8:57 PM
Reposted by Agnes Koczo
After 2 years of shortages, the compounding market for glucagon-like peptide 1 (GLP-1) medication has exploded to include telehealth companies and compounding pharmacies.

This Medical News article discusses GLP-1 drugs.

#MedSky
Are Compounded GLP-1 Drugs Safe?
This Medical News article discusses safety concerns around compounded semaglutide and tirzepatide, including how clinicians can help prevent dosing errors.
jamanetwork.com
January 24, 2025 at 4:21 PM
Reposted by Agnes Koczo
Anticoagulation & Antiplatelet Therapy for #AFib & Stable CAD: Meta-analysis of RCTs

Will this finally change the practice?

#CardioSky #MedSky
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @hmkyale.bsky.social @csilvers.bsky.social @load-dependent.bsky.social
January 21, 2025 at 9:35 PM
Reposted by Agnes Koczo
Really thought-provoking. Sensible arguments by John G. F. Cleland in JAMA cardiology question long-term aspirin in secondary prevention. jamanetwork.com/journals/jam....
December 8, 2024 at 9:17 PM
Reposted by Agnes Koczo
#Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery
(ASSURE-DES)

Article www.jacc.org/doi/10.1016/...
Editorial www.jacc.org/doi/10.1016/...
#CardioSky #JACC #MedSky
@jaccjournals.bsky.social
December 7, 2024 at 3:30 PM
Reposted by Agnes Koczo
Most viewed in the last 7 days from JAMA: Muvalaplin reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated.

https://ja.ma/4eHAXLq
November 23, 2024 at 12:00 PM